Consent given pursuant to sections 14 and 14A to the importation and supply of the therapeutic goods specified by Otsuka Australia Pharmaceutical

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for the quality, efficacy, and safety of therapeutic goods, including medicines, in Australia. This legislation was introduced to address the need for a unified regulatory system governing therapeutic goods, ensuring they meet the necessary standards before entering the market. The Act was enacted by the Commonwealth Parliament, with the policy objective of protecting public health by controlling the quality and safety of therapeutic goods available in Australia. This particular amendment in 2016, concerning the consent for the importation and supply of tolvaptan (SAMSCA) 15 mg tablet blister packs, allows for flexibility in certain regulatory requirements while maintaining oversight to ensure public safety. The consent provided under sections 14 and 14A of the Act enables the importation and supply of the specified product under particular conditions, reflecting the Act's aim to balance regulatory requirements with the practicalities of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the importation, supply, and advertising of therapeutic goods within Australia, including medicines, medical devices, and other health-related products. This Act encompasses a wide range of industries and businesses, ensuring that all therapeutic goods available in Australia meet specific safety, quality, and efficacy standards. The Act applies nationally across the Commonwealth of Australia, with the Therapeutic Goods Administration (TGA) under the Department of Health being the regulatory body responsible for enforcing the provisions of the Act. Certain exclusions and exemptions may apply, such as for goods that fall under different legislative frameworks or are subject to specific provisions within the Act itself. The Act's scope can be extended or further defined through subordinate instruments, such as regulations and orders, which provide detailed requirements and guidelines for the implementation and enforcement of the Act. In the context of the consent granted under sections 14 and 14A of the Therapeutic Goods Act 1989, the TGA allowed Otsuka Australia Pharmaceutical Pty Ltd to import and supply tolvaptan (SAMSCA) 15 mg tablet blister packs that do not conform to certain labelling requirements specified in TGO 69. This consent, effective from January 11, 2016, until June 2017, is subject to specific conditions, including the use of previously approved labels that have been over-stickered with relevant information, the provision of a 'Dear Pharmacist' letter to ensure proper handling and patient safety, and the establishment of a referral mechanism for any queries or complaints related to the product.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) contains provisions for the regulation of therapeutic goods, including medicines, in Australia. Sections 14 and 14A (14, 14A) of the Act specifically address consent to the importation and supply of therapeutic goods that do not comply with certain legislative requirements. In this case, the Act has been applied to the importation and supply of tolvaptan (SAMSCA) 15 mg tablet blister packs (AUST R 176602) which do not conform with the labelling requirements under paragraph 3(2)(l) of the Therapeutic Goods Order No. 69 (TGO 69). These non-conforming labels do not list the current Australian sponsor for the product, which is Otsuka Australia Pharmaceutical Pty Ltd. Under the Act, the Secretary of the Department of Health may grant consent for the importation and supply of therapeutic goods that do not meet certain requirements, provided that specific conditions are met. In this instance, the consent granted under sections 14 and 14A permits the importation and supply of tolvaptan (SAMSCA) 15 mg tablet blister packs with non-compliant labelling, subject to several conditions. These include the use of previously approved labels that have been over-stickered with relevant warning statements, storage conditions, previous sponsor’s details, and the AUST R number. Additionally, a 'Dear Pharmacist' letter must be provided with each affected batch, advising pharmacists to instruct patients to keep the blisters in their cartons to retain Australian contact details. Lastly, arrangements must be made with the former sponsor, Aspen, to handle any queries or complaints about the product. Entities governed by the Act, such as Otsuka Australia Pharmaceutical Pty Ltd, must adhere to the conditions outlined in the consent to ensure compliance with the regulatory requirements. This includes ensuring that all labels are correctly over-stickered, distributing the 'Dear Pharmacist' letter with each batch, and maintaining an effective communication channel with the former sponsor, Aspen, for handling patient queries or complaints. Non-compliance with these obligations could lead to serious consequences, including enforcement actions by the Therapeutic Goods Administration. Failure to comply with the terms of the consent or the obligations imposed by the Act may result in various penalties and legal consequences. Under the Act, breaches of certain provisions can lead to civil or criminal penalties. For instance, supplying non-compliant therapeutic goods can be considered an offence, with potential penalties including fines and imprisonment. The maximum penalties for contravening the Act can vary depending on the specific provision breached, but they can be substantial, reflecting the importance of compliance with therapeutic goods regulations. Additionally, non-compliance may also result in the revocation of consent, cessation of supply, and other enforcement actions by the Therapeutic Goods Administration.